← Back to Search

Diagnostic Imaging for Tauopathies

Phase < 1
Recruiting
Research Sponsored by University of Pennsylvania
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Participants must be aged between 40 to 85 years and be both male and female
Be older than 18 years old
Must not have
Females who are pregnant or breastfeeding at the time of screening will be excluded
Forms of parkinsonism other than PD, PSP and MSA as defined above
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 8 weeks
Awards & highlights
No Placebo-Only Group

Summary

This trial aims to create a radiotracer to accurately detect brain diseases such as Parkinson's, Multiple System Atrophy, Progressive Supranuclear Palsy, and Frontotemporal Dementia. It is a multicenter trial with U Penn, Pitt, Yale, UCSF, and WU.

Who is the study for?
This trial is for adults aged 40-85 with Parkinson's Disease, Multiple System Atrophy, Progressive Supranuclear Palsy, Frontotemporal Dementia or healthy controls. They must understand the study and consent to participate. Pregnant women and those with major psychiatric disorders or substance abuse issues are excluded.
What is being tested?
The trial tests new radiotracers' specificity using diagnostic assessments like neurologic exams and brain scans (Amyloid PET and MRI) across multiple sites including U Penn, Pitt, Yale University, UCSF, and WU.
What are the potential side effects?
Potential side effects may include discomfort from the imaging procedures such as headaches or nausea post-scan. Allergic reactions to contrast agents used in MRI/PET scans could occur but are rare.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am between 40 and 85 years old.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I am not pregnant or breastfeeding.
Select...
My condition is not PD, PSP, or MSA.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~8 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 8 weeks for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Disease diagnosis

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Diagnostic AssessmentsExperimental Treatment3 Interventions
Subjects may receive an Amyloid PET scan, a brain MRI and neurological exam with diagnostic assessments.

Find a Location

Who is running the clinical trial?

University of PennsylvaniaLead Sponsor
2,076 Previous Clinical Trials
42,719,731 Total Patients Enrolled
2 Trials studying Tauopathies
140 Patients Enrolled for Tauopathies
~36 spots leftby Jul 2028
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top